LaMattina, John C <br/><br/>
Alemtuzumab as compared to alternative contemporary induction regimens.  [electronic resource] 

 -  Transplant international : official journal of the European Society for Organ Transplantation  May 2012 
 - 518-26 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1432-2277 
<br/><br/><label>Standard No.: </label>10.1111/j.1432-2277.2012.01448.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antilymphocyte Serum--therapeutic use<br/>Basiliximab<br/>Female<br/>Graft Rejection--etiology<br/>Graft Survival<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Infections--etiology<br/>Kaplan-Meier Estimate<br/>Kidney Transplantation--adverse effects<br/>Leukopenia--etiology<br/>Male<br/>Middle Aged<br/>Recombinant Fusion Proteins--therapeutic use<br/>Retrospective Studies<br/>Risk Factors<br/>Treatment Outcome